Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Vaxart, Inc Common Stock (VXRT)

Biological Products, (no Disgnostic Substances)

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

170 HARBOR WAY, SUITE 300
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/26/1990

Market Cap

172,762,664

Shares Outstanding

152,040,000

Weighted SO

153,408,995

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

INO --.--%

IBIO --.--%

CODX --.--%

NVAX --.--%

OCGN --.--%

Beta

0.6510

Last Div

0.0000

Range

0.52-1.54

Chg

0.0163

Avg Vol

4173977

Mkt Cap

172762664

Exch

NASDAQ

Country

US

Phone

650 550 3500

DCF Diff

0.9798

DCF

-0.2630

Div Yield

0.0000

P/S

14.0766

EV Multiple

-2.2145

P/FV

1.7534

Div Yield %

0.0000

P/E

-1.8544

PEG

-0.0577

Payout

0.0000

Current Ratio

4.5402

Quick Ratio

4.5402

Cash Ratio

2.7472

DSO

142.0684

DIO

0.0000

Op Cycle

142.0684

DPO

284.6207

CCC

-142.5523

Gross Margin

0.6252

Op Margin

-6.1149

Pretax Margin

-6.1419

Net Margin

-6.1646

Eff Tax Rate

-0.0037

ROA

-0.6651

ROE

-1.1419

ROCE

-0.7659

NI/EBT

1.0037

EBT/EBIT

1.0044

EBIT/Rev

-6.1149

Debt Ratio

0.0628

D/E

0.0893

LT Debt/Cap

0.0195

Total Debt/Cap

0.0820

Int Coverage

-58.8612

CF/Debt

-8.6362

Equity Multi

1.4216

Rec Turnover

2.5692

Pay Turnover

1.2824

Inv Turnover

0.0000

FA Turnover

0.3727

Asset Turnover

0.1079

OCF/Share

-0.3343

FCF/Share

-0.3379

Cash/Share

0.3389

OCF/Sales

-5.0306

FCF/OCF

1.0110

CF Coverage

-8.6362

ST Coverage

-11.1083

CapEx Coverage

-90.9278

Div&CapEx Cov

-90.9278

P/BV

1.7534

P/B

1.7534

P/S

14.0766

P/E

-1.8544

P/FCF

-2.7678

P/OCF

-2.2724

P/CF

-2.2724

PEG

-0.0577

P/S

14.0766

EV Multiple

-2.2145

P/FV

1.7534

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 13, 20:52 Vaxart Announces Preliminary Results of Annual Meeting of Stockholders GlobeNewswire Inc. Jan 19, 08:30 Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate GlobeNewswire Inc. Jan 16, 09:25 Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management GlobeNewswire Inc. Jan 16, 09:22 Vaxart, Inc. Announces Management Change

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.18 11/09/2012 10/25/2012 10/26/2012 11/30/-0001